Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (613)	3/26/1998 6:37:00 PM
From: 5,17,37,5,101,...	Read Replies (1) \| Respond to of 756

Charles, I posted answer previously: Message 3812540 This goes to show just how poorly thought out IvAm's strategy was regarding Paxene and how poorly managed IvAm is. Much of their problem is a void of leadership over disparate parts, i.e. the hand doesn't know what the mouth is doing. For example, I called and spoke to Jaffee once in IR and asked him if management was upbeat, a fairly easy question to dodge. Well he said that at HQ people were elated but he didn't have any idea what anyone thought in other divisions or subsidiaries. Typical. We refer to IVX as IvAm because as the stock was careening to $6.00 recently, our fearless leader, Professor Frost, was quoted in a local Miami article, briefly tipping his hand, that he wanted to acquire PanAm. What a lack of focus! Ambivalence. Etc. Jackson